JY
DMRA

Jeff Yass’s Damora Therapeutics DMRA Stock Holding History

Jeff Yass’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
12,009
+2,239
+23% +$54.2K ﹤0.01% 10959
2026
Q1 		$253K Buy
+9,770
New +$251K ﹤0.01% 11245
2025
Q3 		– Sell
-13,602
Closed -$45.2K – 12951
2025
Q2 		$45.2K Buy
13,602
+2,880
+27% +$8.52K ﹤0.01% 12143
2025
Q1 		$33.2K Buy
+10,722
New +$50.5K ﹤0.01% 11981
2024
Q3 		– Sell
-6,734
Closed -$79.8K – 12359
2024
Q2 		$79.8K Buy
+6,734
New +$106K ﹤0.01% 11175
2024
Q1 		– Sell
-1,101
Closed -$19.8K – 12595
2023
Q4 		$19.8K Buy
+1,101
New +$16.9K ﹤0.01% 11977
2023
Q3 		– Sell
-3,837
Closed -$242K – 12355
2023
Q2 		$242K Buy
3,837
+1,316
+52% +$71.7K ﹤0.01% 9881
2023
Q1 		$125K Buy
2,521
+1,012
+67% +$53.4K ﹤0.01% 11086
2022
Q4 		$43.4K Sell
1,509
-600
-28% -$24.9K ﹤0.01% 11467
2022
Q3 		$99K Buy
+2,109
New +$107K ﹤0.01% 11713
2022
Q1 		– Sell
-639
Closed -$48K – 13364
2021
Q4 		$48K Buy
+639
New +$50.2K ﹤0.01% 12570

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Jeff Yass's DMRA Position: Q2 2026 in Review

Jeff Yass increased its Damora Therapeutics (DMRA) stake by 23% in Q2 2026, buying an estimated $54.2K and bringing the position to 12,009 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #10959.

Jeff Yass first reported a position in DMRA in Q4 2021 and has held it in 11 quarters since. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Jeff Yass held 12,009 shares of Damora Therapeutics worth $312K as of Q2 2026.
  • Jeff Yass bought 2,239 Damora Therapeutics shares in Q2 2026, an estimated $54.2K.
  • Damora Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10959 holding.
  • Jeff Yass first reported a position in Damora Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.